Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Mesenchymal Stem Cells: a Promising Therapeutic Tool for Acute Kidney Injury.

Selim RE., Ahmed HH., Abd-Allah SH., Sabry GM., Hassan RE., Khalil WKB.

Animal Study with a reported sample of 10 on Chronic Kidney Disease, Acute Kidney Injury, published in Appl Biochem Biotechnol (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Appl Biochem Biotechnol (2019)
Country
United States
Reported sample size
10
Source database
PubMed
PMID
30976980
DOI
10.1007/s12010-019-02995-2

Abstract (original English)

Acute kidney injury (AKI) is a rapid loss of renal function. It has high mortality rates. Still, renal replacement therapy is considered the best solution for recovering AKI. This opens a line of thought to develop an alternative therapy for it without complications. Mesenchymal stem cells are considered a new therapy for treating kidney diseases. The aim of this work was to address the anti-apoptotic, antioxidative, and pro-angiogenic effects of adipose tissue-derived MSCs (AD-MSCs) and bone marrow-MSCs (BM-MSCs) for treating AKI. Adult male Wistar rats were assigned into nine groups (n = 10): (1) the control group; (2) the AKI group, receiving cisplatin; (3) the AKI group treated with AD-MSCs (1 × 10 6 ); (4) the AKI group treated with AD-MSCs (2 × 10 6 ); (5) the AKI group treated with AD-MSCs (4 × 10 6 ); (6) the AKI group treated with losartan; (7) the AKI group treated with BM-MSCs (1 × 10 6 ); (8) the AKI group treated with BM-MSCs (2 × 10 6 ); and (9) the AKI group treated with BM-MSCs (4 × 10 6 ). The results showed a significant rise in creatinine, urea, and cystatin C (cys C) levels and upregulation of p38 mRNA, whereas a significant decline in NAD(P)H quinone oxidoreductase 1 (NQO-1) protein and downregulation of B-cell lymphoma-2 (Bcl-2) mRNA and vascular endothelial growth factor (VEGF) mRNA were recorded in AKI. MSCs could improve renal functions manifested by de

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Acute Kidney InjuryAdipose TissueAnimalsAntineoplastic AgentsCisplatinMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsRatsRats, Wistar

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research